Sorrento Therapeutics Inc (SRNE)

[James salmon]

“- Celularity stockholders (including Sorrento Therapeutics, affiliates of Bristol Myers Squibb, Starr Insurance Companies, and Dragasac Limited, a wholly owned subsidiary of Genting Berhad), GX Acquisition Corp. stockholders and PIPE stockholders will hold shares in the combined company that is expected to have an estimated initial post-transaction equity value of approximately $1.7 billion.”

Well from this if SRNE holds 25% then 400 million+